Ferring buys rights to Xanodyne's Lysteda

SAINT-PREX, Switzerland Ferring Pharmaceuticals has bought global rights to a women’s health drug made by U.S. drug maker Xanodyne Pharmaceutical, Ferring said Monday.

Ferring, based in Switzerland bought the rights to Lysteda (tranexamic acid), used to treat women with cyclic heavy menstrual bleeding, a condition estimated to affect up to 22 million women in the United States. The Food and Drug Administration approved the drug in November. Financial terms of the deal were not disclosed.

“Ferring, as a global, privately held biopharmaceutical company, has a long-standing commitment to the health of women worldwide,” Ferring Holding chief executive Michel Pettigrew said in a statement. “The acquisition of Lysteda, in addition to our ongoing support of research and medical education in the field of reproductive health, demonstrates this significant commitment and represents an important addition to our women’s health portfolio.”

Login or Register to post a comment.